Combination therapy with levofloxacin and cefepime to treat severe respiratory infection due to
            Aeromonas caviae
            after a near‐drowning accident in river water

Background: A recent ongoing pandemic of coronavirus disease named coronavirus disease 2019 (COVID-19) has spread in Syria from March 2020 with a pattern of a slow case increase. So far, the government has put the country under lock-down orders as a preventive measure. However, there is a considerable belief in the medical community of our country supposes that the virus has previously passed through the country depending on the high numbers of diagnosed severe respiratory infections early in 2020. Thus, this study was designed to determine the number of people with detectable antibodies to SARS-CoV-2 from two samples of healthy adults with and without a previous history of severe respiratory infection in the last 6 months of the study. Materials and Methods: To this end, samples were collected from 123 and 198 subjects with a previous severe respiratory infection and healthy controls, respectively. Then, immunoglobulin M (IgM) and IgG anti-SARS-CoV-2 antibodies were tested as well. Results: None of the samples from both groups tested IgG positive in the assay while four tested IgM samples were positive. Accordingly, these positive samples were re-analyzed and remained IgM positive in the second test although the reverse transcriptase-polymerase chain reaction for the SARS-CoV-2 virus was negative. Conclusion: Based on our findings, there is no evidence concerning the previous COVID-19 infection in Syria thus it is suggested that all isolation and lock-down orders should be respected as an effective preventive tool in this regard.

Download Full-text

CLINICO-PATHOLOGIC CONFERENCE: 18-MONTH-OLD BOY WITH FEVER AND SEVERE RESPIRATORY INFECTION

Pediatric Pathology & Molecular Medicine ◽

10.1080/15227950290104814 ◽

2002 ◽

Vol 21 (5) ◽

pp. 491-506

Author(s):

William F. Pomputius ◽

Atilano Lacson ◽

Herbert H. Pomerance

Keyword(s):

Respiratory Infection ◽

Severe Respiratory Infection

Download Full-text

Familial susceptibility to severe respiratory infection in early life

Pediatric Pulmonology ◽

10.1002/ppul.20096 ◽

2004 ◽

Author(s):

Tessa Goetghebuer ◽

Dominic Kwiatkowski ◽

Anne Thomson ◽

Jeremy Hull

Keyword(s):

Respiratory Infection ◽

Early Life ◽

Severe Respiratory Infection

Download Full-text

Familial susceptibility to severe respiratory infection in early life

Pediatric Pulmonology ◽

10.1002/ppul.20069 ◽

2004 ◽

Vol 38 (4) ◽

pp. 321-328 ◽

Cited By ~ 28

Author(s):

Tessa Goetghebuer ◽

Dominic Kwiatkowski ◽

Anne Thomson ◽

Jeremy Hull

Keyword(s):

Respiratory Infection ◽

Early Life ◽

Severe Respiratory Infection

Download Full-text

Prison and community outbreak of severe respiratory infection due to adenovirus type 14p1 in Tayside, UK

Journal of Public Health ◽

10.1093/pubmed/fdu009 ◽

2014 ◽

Vol 37 (1) ◽

pp. 64-69 ◽

Cited By ~ 10

Author(s):

B. J. Parcell ◽

P. G. McIntyre ◽

D. L. Yirrell ◽

A. Fraser ◽

M. Quinn ◽

...

Keyword(s):

Respiratory Infection ◽

Adenovirus Type ◽

Severe Respiratory Infection

Download Full-text

Human Adenovirus Associated with Severe Respiratory Infection, Oregon, USA, 2013–2014

Emerging Infectious Diseases ◽

10.3201/eid2206.151898 ◽

2016 ◽

Vol 22 (6) ◽

pp. 1044-1051 ◽

Cited By ~ 66

Author(s):

Magdalena Kendall Scott ◽

Christina Chommanard ◽

Xiaoyan Lu ◽

Dianna Appelgate ◽

LaDonna Grenz ◽

...

Keyword(s):

Respiratory Infection ◽

Human Adenovirus ◽

Severe Respiratory Infection

Download Full-text

Identification and Epidemiology of Severe Respiratory Disease due to Novel Swine-Origin Influenza A (H1N1) Virus Infection in Alberta

Canadian Journal of Infectious Diseases and Medical Microbiology ◽

10.1155/2010/293098 ◽

2010 ◽

Vol 21 (4) ◽

pp. e151-e157

Author(s):

George Zahariadis ◽

Ari R Joffe ◽

James Talbot ◽

Albert deVilliers ◽

Patricia Campbell ◽

...

Keyword(s):

United States ◽

Respiratory Infection ◽

Influenza A ◽

Respiratory Illness ◽

The United States ◽

Molecular Methods ◽

Contact Tracing ◽

Severe Respiratory Distress ◽

Influenza A H1n1 ◽

Severe Respiratory Infection

BACKGROUND: In March 2009, global surveillance started detecting cases of influenza-like illness in Mexico. By mid-April 2009, two pediatric patients were identified in the United States who were confirmed to be infected by a novel influenza A (H1N1) strain. The present article describes the first identified severe respiratory infection and the first death associated with pandemic H1N1 (pH1N1) in Canada.METHODS: Enhanced public health and laboratory surveillance for pH1N1 was implemented throughout Alberta on April 24, 2009. Respiratory specimens from all patients with a respiratory illness and travel history or those presenting with a severe respiratory infection requiring hospitalization underwent screening for respiratory viruses using molecular methods. For the first severe case identified and the first death due to pH1N1, histocompatibility leukocyte antigens were compared by molecular methods.RESULTS: The first death (a 39-year-old woman) occurred on April 28, 2009, and on May 1, 2009, a 10-year-old child presented with severe respiratory distress due to pH1N1. Both patients had no travel or contact with anyone who had travelled to Mexico; the cases were not linked. Histocompatibility antigen comparison of both patients did not identify any notable similarity. pH1N1 strains identified in Alberta did not differ from the Mexican strain.CONCLUSION: Rapid transmission of pH1N1 continued to occur in Alberta following the first death and the first severe respiratory infection in Canada, which were identified without any apparent connection to Mexico or the United States. Contact tracing follow-up suggested that oseltamivir may have prevented ongoing transmission of pH1N1.

Download Full-text

Lessons learned from COVID-19 outbreaks profile in combination with pathology, diagnosis, treatment and vaccines

E3S Web of Conferences ◽

10.1051/e3sconf/202129203069 ◽

2021 ◽

Vol 292 ◽

pp. 03069

Author(s):

Ruizhe Liu ◽

Enqi Zhang

Keyword(s):

Public Health ◽

Infectious Disease ◽

Disease Control ◽

Respiratory Infection ◽

Surveillance System ◽

Lessons Learned ◽

Chinese Government ◽

Basic Information ◽

Health It ◽

Severe Respiratory Infection

COVID-19 is an infectious disease caused by the SARS-CoV-2 virus, which may lead to severe respiratory infection. Since December 2019, the first COVID-19 case was detected in Wuhan, Hubei Province, China. The virus has been spread worldwide, and many countries are still struggling with disease control. Therefore, this revision would provide experience accumulated and the lessons learned by China in the pandemic. The current work reviewed the basic information about COVID-19 in the aspects of pathology, diagnosis, treatment, prevention, and the major pandemic outbreaks in China. By summarizing and analyzing the measurements taken by the Chinese government and their corresponding outcomes on public health, it determined the progress made on the policies and their efficiency in the control of pandemics. With the sharing of these lessons, other countries can learn from establishing the COVID-19 surveillance system in China that would support their struggle on domestic public health.

Download Full-text

Common variable hypogammaglobulinemia and severe respiratory infection by influenza B virus in pediatric patient

Journal of Allergy and Clinical Immunology ◽

10.1016/s0091-6749(02)81725-0 ◽

2002 ◽

Vol 109 (1) ◽

pp. S197-S197 ◽

Cited By ~ 1

Author(s):

Cristina Jacob ◽

Angela Fomin ◽

Ana Paula Castro ◽

Renata Santoro ◽

Jacques Sztajnbok ◽

...

Keyword(s):

Pediatric Patient ◽

Respiratory Infection ◽

Influenza B Virus ◽

Influenza B ◽

B Virus ◽

Severe Respiratory Infection ◽

Common Variable

Download Full-text

Treatment of COVID-19 patients using plasma therapy: Letter to Editor

Journal of Birjand University of Medical Sciences ◽

10.32592/jbirjandunivmedsci.2021.28.1.109 ◽

2020 ◽

pp. 84-87

Keyword(s):

Side Effects ◽

Respiratory Infection ◽

Therapeutic Approach ◽

Population Studies ◽

Specific Drug ◽

Plasma Therapy ◽

Severe Respiratory Infection

The symptoms of COVID-19, caused by the newly known type of coronavirus, vary widely from asymptomatic, mild to severe respiratory infection leading to hospitalization or death of patients. To date, no specific drug has been reported for the treatment of patients affected by this virus. One of the approaches adopted for the treatment of this disease is the use of plasma therapy, which contains antibodies against the virus. Following of the plasma therapy have not been reported any serious side effects. Currently, the numbers of these studies are limited, and evaluation of the larger population studies can provide stronger evidence for treating physicians about the effectiveness of this therapeutic approach.

Download Full-text